Security key
578784100
Maze Therapeutics, Inc. - Common Stock (MAZE)
CUSIP: 578784100
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 504,174
- Total 13F value
- $15,044,336
- Share change
- -120,526
- SEC-reported price per share
- $29.84
- Number of holders
- 17
- Value change
- -$3,599,356
- Number of buys
- 6
- Number of sells
- 14
- Shares outstanding
- 55,150,259
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
17
Top holders
10
MAZE full security history
Ownership snapshot
Full 13F holder table
Maze Therapeutics, Inc. SEC filings
Maze Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 578784100
Recent filing periods:
Ownership snapshot
Top reported holders of MAZE - Maze Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ARCH Venture Fund X, L.P.
Disclosed value leader
Third Rock Ventures IV, L.P.
Comparable rows
15/15
Latest evidence
30 Jun 2026
13D/G
3/4/5
13F
Lead comparable stake: 9.4%
13D/G row: ARCH Venture Fund X, L.P.
Showing 1-6 of 15 holder rows.
Quick read
ARCH Venture Fund X, L.P. leads the comparable SEC ownership view at 9.4%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ARCH Venture Fund X, L.P.'s linked filing trail.
Comparable ownership
Top 5
ARCH Venture Fund X, L.P.
9.4%
Third Rock Ventures IV, L.P.
9.3%
Deep Track Capital, LP
9%
Frazier Life Sciences Public Fund...
9%
Paradigm Biocapital Advisors LP
6.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ARCH Venture Fund X, L.P. |
13D/G
|
9.4%
|
$36,215,266
4,120,053 shares
|
$0 | 31 Mar 2025 |
| Third Rock Ventures IV, L.P. |
13D/G
3/4/5
10%+ Owner
|
9.3%
|
$179,808,372
4,473,958 shares
|
-$64,304,000 | 31 Dec 2025 |
| Deep Track Capital, LP |
13F
13D/G
Company
|
9%
from 13D/G
|
$103,805,226
3,477,562 shares
|
— | 31 Mar 2026 |
| Frazier Life Sciences Public Fund, L.P. |
13D/G
|
9%
|
$174,515,671
4,342,266 shares
|
+$39,762,017 | 31 Dec 2025 |
| Paradigm Biocapital Advisors LP |
13D/G
13F
Company
|
6.1%
|
$155,788,502
3,051,087 shares
|
$0 | 25 Mar 2026 |
| Janus Henderson Group Ltd. |
13F
13D/G
Company · JANUS HENDERSON GROUP PLC
|
5.8%
from 13D/G
|
$85,280,271
2,858,876 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
17
Shares
504,174
Rows available
17
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
164
Q2 2026 holders
17
Holder diff
-147
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend